The preferred initial and most widely used pharmacological agent for T2DM is metformin, which decreases glucose production by inhibiting the mitochondrial glycerophosphate dehydrogenase (GPDH, GPD2) [7]. The gene discussed is GPD2; the disease is type 2 diabetes mellitus.